Skip to content

Peripheral blood inflammatory index in the diagnosis and prognosis of prostate cancer

Peripheral blood inflammatory index in the diagnosis and prognosis of prostate cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029074
Enrollment
Unknown
Registered
2020-01-13
Start date
2020-01-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

BPH group+PCa group:none

Sponsors

Nanfang Hospital, Southern Medical University.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) 18 to 80 years of age; (2) patients who were hospitalized and had received at least one follow-up visit before December 31, 2018; (3) patients diagnosed with prostatic hyperplasia or prostate cancer in our hospital who have undergone prostate puncture or prostate surgery.

Exclusion criteria

Exclusion criteria: (1) suffering from acute inflammation, infection, acute renal failure, inflammatory bowel disease, connective tissue disease and so on; (2) patients with liver cancer, lung cancer, stomach cancer and other malignant tumors or metastasis; (3) patients with congenital disease or mental illness, or uncooperative with consciousness disorder; (4) long-term use of hormones or surgical injuries within one month.

Design outcomes

Primary

MeasureTime frame
WBC;NEU;LYM;EOS;BAOS;PSA;sex hormones;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactShuhua He

Nanfang Hospital, Southern Medical University

Heshuhua1975@163.com+86 18520507691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026